Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 17

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner

Zhang, Yiwei, Zeng, Shelya X., Hao, Qian, Lu, Hua · 2017 · Developmental Biology

Abstract

Although p53 is not essential for normal embryonic development, it plays a pivotal role in many biological and pathological processes, including cell fate determination-dependent and independent events and diseases. The expression and activity of p53 largely depend on its two biological inhibitors, MDM2 and MDMX, which have been shown to form a complex in order to tightly control p53 to an undetectable level during early stages of embryonic development. However, more delicate studies using conditional gene-modification mouse models show that MDM2 and MDMX may function separately or synergistically on p53 regulation during later stages of embryonic development and adulthood in a cell and tissue-specific manner. Here, we report the role of the MDM2/MDMX-p53 pathway in pancreatic islet morphogenesis and functional maintenance, using mouse lines with specific deletion of MDM2 or MDMX in pancreatic endocrine progenitor cells. Interestingly, deletion of MDM2 results in defects of embryonic endocrine pancreas development, followed by neonatal hyperglycemia and lethality, by inducing pancreatic progenitor cell apoptosis and inhibiting cell proliferation. However, unlike MDM2-knockout animals, mice lacking MDMX in endocrine progenitor cells develop normally. But, surprisingly, the survival rate of adult MDMX-knockout mice drastically declines compared to control mice, as blockage of neonatal development of endocrine pancreas by inhibition of cell proliferation and subsequent islet dysfunction and hyperglycemia eventually lead to type 1 diabetes-like disease with advanced diabetic nephropathy. As expected, both MDM2 and MDMX deletion-caused pancreatic defects are completely rescued by loss of p53, verifying the crucial role of the MDM2 and/or MDMX in regulating p53 in a spatio-temporal manner during the development, functional maintenance, and related disease progress of endocrine pancreas. Also, our study suggests a possible mouse model of advanced diabetic nephropathy, which is complementary to other established diabetic models and perhaps useful for the development of anti-diabetes therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ydbio.2017.01.014

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 65

  1. Aguilar-Bryan, 2008, Neonatal diabetes mellitus, Endocr. Rev., 29, 265, 10.1210/er.2007-0029 · DOI · Paper page
  2. Allagnat, 2013, Connexin36 contributes to INS-1E cells survival through modulation of cytokine-induced oxidative stress, ER stress and AMPK activity, Cell Death Differ., 20, 1742, 10.1038/cdd.2013.134 · DOI
  3. Antoniali, 2014, Emerging roles of the nucleolus in regulating the DNA damage response: the noncanonical DNA repair enzyme APE1/Ref-1 as a paradigmatical example, Antioxid. Redox Signal, 20, 621, 10.1089/ars.2013.5491 · DOI
  4. Asahara, 2009, Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes, Biochem. Biophys. Res. Commun., 381, 367, 10.1016/j.bbrc.2009.02.047 · DOI
  5. Ashery-Padan, 2000, Pax6 activity in the lens primordium is required for lens formation and for correct placement of a single retina in the eye, Genes Dev., 14, 2701, 10.1101/gad.184000 · DOI · Paper page
  6. Ashery-Padan, 2004, Conditional inactivation of Pax6 in the pancreas causes early onset of diabetes, Dev. Biol., 269, 479, 10.1016/j.ydbio.2004.01.040 · DOI
  7. Betz, 2014, Recent advances in animal models of diabetic nephropathy. nephron, Exp. Nephrol., 126, 191, 10.1159/000363300 · doi:10.1159/000363300
  8. Betz, 2016, An update on the use of animal models in diabetic nephropathy research, Curr. Diabetes Rep., 16, 18, 10.1007/s11892-015-0706-2 · DOI
  9. Bitti, 2011, Genotypes of p53 codon 72 correlate with age at onset of type 1 diabetes in a sex-specific manner, J. Pediatr. Endocrinol. Metab., 24, 437, 10.1515/jpem.2011.058 · DOI
  10. Boominathan, 2010, The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network, Cancer Metastasis Rev., 29, 613, 10.1007/s10555-010-9257-9 · DOI
  11. Breyer, 2005, Mouse models of diabetic nephropathy, J. Am. Soc. Nephrol., 16, 27, 10.1681/ASN.2004080648 · DOI · Paper page
  12. Brighenti, 2014, Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer, Oncogene, 33, 4396, 10.1038/onc.2014.1 · DOI
  13. Burgdorf, 2011, Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans, PLoS One, 6, e15813, 10.1371/journal.pone.0015813 · DOI
  14. Cano, 2007, Pancreatic development and disease, Gastroenterology, 132, 745, 10.1053/j.gastro.2006.12.054 · DOI
  15. Chawla, 2010, Role of the renin angiotensin system in diabetic nephropathy, World J. Diabetes, 1, 141, 10.4239/wjd.v1.i5.141 · DOI
  16. Chen, 1993, Mapping of the p53 and mdm-2 interaction domains, Mol. Cell. Biol., 13, 4107, 10.1128/MCB.13.7.4107 · DOI · Paper page
  17. Cleary, 2009, Minireview: obesity and breast cancer: the estrogen connection, Endocrinology, 150, 2537, 10.1210/en.2009-0070 · DOI · Paper page
  18. Dai, 2004, Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5, J. Biol. Chem., 279, 44475, 10.1074/jbc.M403722200 · DOI · Paper page
  19. Di Cesare, 2001, Serum anti-p53 autoantibodies in patients with type 1 diabetes, Ann. Clin. Lab. Sci., 31, 253
  20. Donath, 2011, Type 2 diabetes as an inflammatory disease, Nat. Rev. Immunol., 11, 98, 10.1038/nri2925 · DOI · Paper page
  21. Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
  22. Doyle, S.L., Donohoe, C.L., Lysaght, J., Reynolds, J.V., 2012. Visceral obesity, metabolic syndrome, insulin resistance and cancer. The Proceedings of the Nutrition Society 71, 181-189. · DOI · Paper page
  23. Fomina-Yadlin, 2012, GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity, PLoS One, 7, e28808, 10.1371/journal.pone.0028808 · DOI
  24. Fujita, 2012, A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment, Exp. Anim./Jpn. Assoc. Lab. Anim. Sci., 61, 49, 10.1538/expanim.61.49 · DOI
  25. Glaser, 1994, Absence of PAX6 gene mutations in Gillespie syndrome (partial aniridia, cerebellar ataxia, and mental retardation), Genomics, 19, 145, 10.1006/geno.1994.1024 · DOI
  26. Gloria-Bottini, 2011, Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases, Diabetes Res. Clin. Pract., 91, e64, 10.1016/j.diabres.2010.11.031 · doi:10.1016/j.diabres.2010.11.031
  27. Grier, 2002, Conditional allele of mdm2 which encodes a p53 inhibitor, Genesis, 32, 145, 10.1002/gene.10066 · DOI
  28. He, 2014, AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity, Mol. Cell. Biol., 34, 148, 10.1128/MCB.00670-13 · DOI
  29. Hill, 2000, Pancreatic development and adult diabetes, Pediatr. Res., 48, 269, 10.1203/00006450-200009000-00002 · DOI
  30. Hilliard, 2011, Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching, Dev. Biol., 353, 354, 10.1016/j.ydbio.2011.03.017 · DOI
  31. Hoshino, A., Ariyoshi, M., Okawa, Y., Kaimoto, S., Uchihashi, M., Fukai, K., Iwai-Kanai, E., Ikeda, K., Ueyama, T., Ogata, T., Matoba, S., 2014. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. Proceedings of the National Academy of Sciences of the United States of America 111. pp. 3116–3121. · DOI · Paper page
  32. Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  33. Jin, 2006, 14-3–3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation, EMBO J., 25, 1207, 10.1038/sj.emboj.7601010 · DOI
  34. Jonkers, 2001, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer, Nat. Genet., 29, 418, 10.1038/ng747 · DOI · Paper page
  35. Kaur, 2014, Rodent animal models: from mild to advanced stages of diabetic nephropathy, Inflammopharmacology, 22, 279, 10.1007/s10787-014-0215-y · DOI
  36. Kawai, 2007, RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity, Cancer Res., 67, 6026, 10.1158/0008-5472.CAN-07-1313 · DOI
  37. Kung, 2016, The P72R polymorphism of p53 Predisposes to obesity and metabolic dysfunction, Cell Rep., 14, 2413, 10.1016/j.celrep.2016.02.037 · DOI · Paper page
  38. Lane, 2010, p53 research: the past thirty years and the next thirty years, Cold Spring Harb. Perspect. Biol., 2, a000893, 10.1101/cshperspect.a000893 · DOI · Paper page
  39. Lim, 2013, Ribosomal S6 Kinase 2 (RSK2) maintains genomic stability by activating the Atm/p53-dependent DNA damage pathway, PLoS One, 8, e74334, 10.1371/journal.pone.0074334 · DOI
  40. Linke, 2008, Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans, Cell Death Differ., 15, 841, 10.1038/sj.cdd.4402309 · DOI · Paper page
  41. Mihailidou, 2015, Regulation of P21 during diabetes-associated stress of the endoplasmic reticulum, Endocr. Relat. Cancer, 22, 217, 10.1530/ERC-15-0018 · DOI
  42. Momand, 1992, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation, Cell, 69, 1237, 10.1016/0092-8674(92)90644-R · DOI · Paper page
  43. Nalabothula, 2010, The nucleolus takes control of protein trafficking Under cellular stress, Mol. Cell Pharm., 2, 203
  44. Nelson, 2013, 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology, Science, 342, 1094, 10.1126/science.1241908 · DOI · Paper page
  45. O'Dowd, 2013, Endocrine pancreatic development: impact of obesity and diet, Front. Physiol., 4, 170, 10.3389/fphys.2013.00170 · DOI
  46. Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
  47. Padgett, 2013, The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis, Ann. N.Y. Acad. Sci., 1281, 16, 10.1111/j.1749-6632.2012.06826.x · DOI · Paper page
  48. Park, J., Sarode, V.R., Euhus, D., Kittler, R., Scherer, P.E., 2012. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 109. pp. 21058–21063. · DOI · Paper page
  49. Ren, 2016, Permissive role of AMPK and autophagy in adiponectin deficiency-accentuated myocardial injury and inflammation in endotoxemia, J. Mol. Cell. Cardiol., 93, 18, 10.1016/j.yjmcc.2016.02.002 · DOI
  50. Ryu, 2014, Hyperglycemia as a risk factor for cancer progression, Diabetes Metab. J., 38, 330, 10.4093/dmj.2014.38.5.330 · DOI · Paper page
  51. Saran, 2015, US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States, Am. J. Kidney Dis.: Off. J. Natl. Kidney Found., 66, 10.1053/j.ajkd.2015.05.001 · DOI · Paper page
  52. Shadfan, 2012, MDM2 and MDMX: alone and together in regulation of p53, Transl. Cancer Res., 1, 88
  53. Shield, 2007, Neonatal diabetes: how research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life, Horm. Res., 67, 77
  54. Shikata, 2013, Diabetes mellitus and cancer risk: review of the epidemiological evidence, Cancer Sci., 104, 9, 10.1111/cas.12043 · DOI · Paper page
  55. Soler, 2012, New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy, Exp. Diabetes Res., 2012, 616313, 10.1155/2012/616313 · DOI
  56. Sun, 2007, 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction, J. Biol. Chem., 282, 8052, 10.1074/jbc.M610621200 · DOI · Paper page
  57. Takahashi, 2014, Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice, J. Diabetes Res., 2014, 590541, 10.1155/2014/590541 · DOI
  58. Tornovsky-Babeay, 2014, Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells, Cell Metab., 19, 109, 10.1016/j.cmet.2013.11.007 · DOI · Paper page
  59. Wang, 2012, Mdm2 and MdmX partner to regulate p53, FEBS Lett., 586, 1390, 10.1016/j.febslet.2012.02.049 · DOI
  60. Wellen, 2005, Inflammation, stress, and diabetes, J. Clin. Investig., 115, 1111, 10.1172/JCI25102 · DOI · Paper page
  61. Wilson, 2003, Gene expression cascades in pancreatic development, Mech. Dev., 120, 65, 10.1016/S0925-4773(02)00333-7 · DOI · Paper page
  62. Yao, 2013, Ultraviolet (UV) and hydrogen peroxide activate ceramide-ER stress-AMPK signaling axis to promote retinal pigment epithelium (RPE) cell apoptosis, Int. J. Mol. Sci., 14, 10355, 10.3390/ijms140510355 · DOI
  63. Zhang, 2003, Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway, Mol. Cell Biol., 23, 8902, 10.1128/MCB.23.23.8902-8912.2003 · DOI · Paper page
  64. Zhang, 2014, Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis, Dev. Biol., 396, 19, 10.1016/j.ydbio.2014.09.017 · DOI
  65. Zheng, 2005, Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function, Diabetes, 54, 1423, 10.2337/diabetes.54.5.1423 · DOI

Cited by

See all 17

Metadata

Authors
Zhang, Y., Zeng, S. X., Hao, Q., & Lu, H.
Venue
Developmental Biology
Publisher
Elsevier BV
Published
2017-03
Volume
423
Issue
1
Pages
34-45
ISSN
0012-1606
Cited by
17
References
16
Language
en
Licence
Funders
NIH-NCI (R01 CA095441, R01CA172468, R01CA127724, R21CA190775, R21CA201889)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. https://app.cochat.ai/papers/10.1016/j.ydbio.2017.01.014
The paper
Zhang, Y., Zeng, S. X., Hao, Q., & Lu, H. (2017). Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Developmental Biology. https://doi.org/10.1016/j.ydbio.2017.01.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.